Targeted theranostics
Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.
1. A theranostic compound comprising a structure according to
and wherein R 1 comprises a carbonyl or a protease-cleavable linker.
2. A method of treating a subject, the method comprising:
1) administering to the subject a theranostic compound comprising:
a) a bioactive component;
b) a detectable component linked to the bioactive component by a linker; and
c) a targeting component,
wherein the theranostic compound has a structure according to
wherein said linker comprises R 1 and R 1 comprises a carbonyl or a protease-cleavable linker, and
wherein the bioactive component is not active and the detectable component is not detectable when the detectable component is linked to the bioactive component by the enzyme-cleavable linker; and
2) measuring a level of the detectable component in a sample from the subject.
3. The method of claim 2 further comprising a second administering of the theranostic compound to the subject according to the level of the detectable component in the sample from the subject.
4. The method of claim 2 further comprising determining an amount of the bioactive component at a target site of the subject.
5. The method of claim 2 wherein a cell-specific activity at a target site of the subject breaks the linker.
6. A method of treating a subject comprising administering to the subject the theranostic compound according to claim 1 .